 Zogenix Inc NASDAQ: ZGNX has announced interim data from an ongoing 12-month Phase 3 open-label extension OLE study of Fintepla fenfluramine in Lennox-Gastaut syndrome LGS. Data showed that fenfluramine oral solution led to a clinically meaningful and sustained reduction in drop seizures. 